Predicting Development of Sub-Clinical Atrial Fibrillation in Device Patients

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Atrial fibrillation (AF) often starts with short episodes of rapid irregular heartbeats that are only detected by implanted pacemakers or defibrillators. Usually people don't know that they have these episodes. Over time, these episodes can happen more often and last for longer periods. In some people, the heart eventually remains permanently in a fast irregular rhythm, known as atrial fibrillation. This condition can lead to strokes and blood clots. If physicians could detect atrial fibrillation at a very early stage they could treat people early and possibly prevent the condition from becoming permanent. People with implanted devices allow a unique opportunity to constantly monitor the heart rhythm so investigators can detect any irregularities immediately. Investigators don't know which people are at risk of developing short episodes of fast irregular heartbeats that can lead to atrial fibrillation. The purpose of this study is to find out if there are proteins or chemical changes in the blood that can predict the risk of developing atrial fibrillation. These chemical changes, also known as biomarkers, may also be able to give investigators other clues about atrial fibrillation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• • Dual chamber permanent pacemaker or defibrillator implanted within previous 10 years

Locations
Other Locations
Canada
University of Ottawa Heart Institute
RECRUITING
Ottawa
Contact Information
Primary
Tammy Knight
tknight@ottawaheart.ca
613-696-7000
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2034-09
Participants
Target number of participants: 500
Authors
Related Therapeutic Areas
Sponsors
Leads: Ottawa Heart Institute Research Corporation
Collaborators: Genome Canada

This content was sourced from clinicaltrials.gov